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The suppressor of cytokine signalling-1 (SOCS-1) gene is frequently silenced in human hepatocellular carcinoma by aberrant
methylation. The aim of this study was to determine if SOCS-1 is inactivated in pancreatic ductal neoplasms, and to investigate if
aberrant methylation of this gene affected the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway.
Aberrant methylation in the CpG island of the SOCS-1 gene was detected in six of 19 (31.6%) human pancreatic cancer cell lines using
methylation-specific PCR, and was associated with a loss or reduction of gene expression in five of the six methylated cell lines.
Thirteen of 60 pancreatic ductal adenocarcinomas (21.7%) and two of 34 intraductal papillary mucinous neoplasms (IPMNs) (5.9%)
had methylated SOCS-1. In contrast, SOCS-1 methylation was not seen in pancreatic normal ductal epithelia (zero out of 15), in
pancreatic intraepithelial neoplasia (PanINs) (zero out of 49) or in the IPMNs without infiltrating cancer (zero out of 20). 5-Aza-20-
deoxycytidine treatment of the SOCS-1-methylated pancreatic cancer cell lines led to restoration of SOCS-1 gene expression.
Interleukin-6, which has been shown to act through the JAK/STAT pathway to increase cell growth, induced modest time and dose-
dependent cell proliferation in a SOCS-1-methylated cell line (PL10, P¼0.015) but not in two unmethylated cell lines. These results
indicate that loss of SOCS-1 gene is associated with transcriptional silencing and may have growth-promoting effects, and that its
methylation is a useful marker of pancreatic cancer.
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Pancreatic ductal adenocarcinoma is a highly malignant neoplasm
that still carries an extremely poor prognosis. Most patients are
diagnosed at an advanced stage of disease, and the incidence and
mortality rates for invasive pancreatic cancer are almost identical.
The 5-year survival rate is 0–2% (Klo ¨ppel, 2000). Characterisation
of the genetic and epigenetic changes involved in the pathogenesis
of pancreatic cancer should help in the development of sensitive
early detection strategies.
Suppressor of cytokine signalling-1 (SOCS-1) is a cytokine-
inducible protein that functions to regulate negatively cytokine
signal transduction pathways by directly interacting with Janus
kinase (JAK) (Endo et al, 1997; Naka et al, 1997; Starr et al, 1997).
The SH2 domain of SOCS-1 binds to a JH1 domain of JAK2 and
inhibits the phosphorylation of JAK2, thus downregulating the
JAK/ signal transducers and activators of transcription (STAT)
pathway (Narazaki et al, 1998; Yasukawa et al, 1999). Several
studies have shown that constitutive overexpression of SOCS-1
inhibits signalling in response to a range of cytokines, including
interferon-g (Brysha et al, 2001), tumour necrosis factor-a (Morita
et al, 2000), interleukin-2 (IL-2) (Sporri et al, 2001), IL-4 and IL-6
(Starr et al, 1997).
Interleukin-6 has been implicated as a mediator of growth
control in several human neoplasms including multiple myeloma
(Hussein et al, 2002), prostatic cancer (Giri et al, 2001) and colonic
cancer (Schneider et al, 2000) and elevation of serum IL-6 level
have been reported in some cancers such as renal cell carcinoma
(Blay et al, 1992), ovarian cancer (Plante et al, 1994), cholangio-
carcinoma (Goydos et al, 1998) and pancreatic cancer (Barber et al,
1999). The binding of IL-6 to its receptor induces homodimerisa-
tion of gp130, which leads to cross-phosphorylation and activation
of the associated JAK2. Signal transducers and activators of
transcriptors 3 is then recruited to the cytoplasmic region of gp130
and phosphorylated by JAK2 (Kishimoto and Kikutani, 2001).
Activated STAT3 forms homodimers, moves into the nucleus and
activates transcription of various genes, including the antiapopto-
tic regulatory protein Bcl-xl and SOCS-1 (Kishimoto and Kikutani,
2001).
The human SOCS-1 gene on chromosome 16p13.3 is a single-
exon gene encoding 211 amino acids (Endo et al, 1997; Naka et al,
1997; Starr et al, 1997). The gene lies within a large CpG island
spanning 2.5kb. Recently, frequent aberrant methylation of the
CpG island of SOCS-1 gene in hepatocellular carcinoma (HCC) and
in multiple myeloma, and it was also demonstrated that the
aberrant methylation had growth suppression activity (Yoshikawa
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set al, 2001; Galm et al, 2002). These results implicate the JAK/STAT
pathway as having growth-promoting properties and suggest that
SOCS-1 may normally suppress growth (Bromberg et al, 1999;
Rottapel et al, 2002).
DNA methylation is a major mechanism for the inactivation of
tumour-suppressor genes in cancer (Jones and Baylin, 2002). We
have previously reported that many benign and malignant
pancreatic neoplasms harbour aberrant methylation at multiple
genes including p16, preproenkephalin, TSLC1, and others
(Fukushima et al, 1997; Ueki et al, 2000; Ueki et al, 2001; Jansen
et al, 2002). In this study, we determined the prevalence and
significance of SOCS-1 methylation in pancreatic neoplasms.
MATERIALS AND METHODS
Cell lines and lymphocytes
Human pancreatic cancer cell lines AsPC1, BxPC3, Capan1,
Capan2, CFPAC1, Mia PaCa2 and Panc-1 were obtained from the
American Type Culture Collection (Rockville, MD, USA) and
Colo357 was purchased from the EACC (Salisbury, UK). Twelve
pancreatic carcinoma cell lines (PL1, 3, 4–6, 8–14) were
generously provided by Dr Elizabeth Jaffee (Johns Hopkins
University). An immortal human pancreatic duct epithelial cell
line, HPDE, was kindly provided by Dr Ming-Sound Tsao
(University of Toronto, Ontario, Canada). All cell lines, except
for HPDE, were cultured in RPMI 1640 medium (Life Technolo-
gies, Inc., Gaithersburg, MD, USA) supplemented with 10% fetal
bovine serum and antibiotics (100U/ml penicillin and 100mgml
 1
streptomycin), and incubated at 371C in a humidified atmosphere
of 5% CO2 in air. HPDE cells were cultured in keratinocyte serum-
free (KSF) medium supplemented by bovine pituitary extract and
epidermal growth factor (Gibco-BRL, Grand Island, NY, USA).
Lymphocyte DNA was collected from 11 healthy individuals after
informed consent as part of an IRB-approved clinical trial that
aims to investigate candidate markers of pancreatic cancer.
Surgically resected pancreatic ductal adenocarcinoma and
intraductal papillary mucinous neoplasms
Sixty primary pancreatic adenocarcinomas and 34 intraductal
papillary mucinous neoplasms (IPMNs) were obtained from
resected surgical specimens at the Johns Hopkins Hospital. The
patients with pancreatic ductal adenocarcinoma included 33 men
and 27 women; mean age was 65.6 years (range, 38–85 years), and
those with IPMN included 17 men and 17 women; mean age was
66.1 years (range, 36–83 years). The IPMNs were histologically
divided into three adenomas, 12 borderline neoplasms, five non-
invasive and 14 invasive adenocarcinomas according to the WHO
classification. Frozen tissues or formalin-fixed paraffin-embedded
tissues were microdissected manually by blade and needle to
obtain greater than 40% neoplastic cellularity in these primary
pancreatic neoplasms. Microdissected tissues were transferred to
tube containing 50–100mlo f1  TK buffer (200mgml
 1 protei-
nase K and 0.5% Tween-20), and incubated at 561C overnight. The
tubes were placed in a 1001C block for 10min for inactivation of
the proteinase K.
Microdissection of normal pancreatic duct epithelia and
PanINs
PanINs was classified into four categories of PanIN-1A, -1B, -2 and
-3 according to the standardised nomenclature and classification
of pancreatic intraepithelial neoplasia (Hruban et al, 2001). Serial
sections (8mm) of formalin-fixed and paraffin-embedded tissue
were stained with haematoxylin & eosin. Microdissection of
normal pancreatic duct epithelium and PanINs including approxi-
mately total 200–1500 cells on three slides each was performed
with a small blade and needle as previously described and
subjected cells to DNA extraction (Fukushima et al, 2002). Forty-
nine PanINs (eight PanIN-1A, 21PanIN-1B, 10PanIN-2 and
10PanIN-3) were collected from 13 pancreata with ductal
adenocarcinoma (mean age of the patients, 64.4 years; range,
50–79 years) and as were 15 samples of normal pancreatic ductal
epithelia (mean age of the patients, 60.9 years; range, 36–79 years).
Methylation-specific PCR
Bisulphite modification of genomic DNA was performed as
previously described (Fukushima et al, 2002). The bisulphite-
treated DNA was amplified with either a methylation-specific or
unmethylation-specific primer set at 40 cycles: 951C for 20s, 571C
for 30s and 721C for 30s. A final extension step was included for
3min at 721C. The methylation-specific primer sequences in exon
1, which lies within the SOCS-1 CpG island, were 50-
TCGTTCGTACGTCGATTATC-30 (sense) and 50-AAAAAAATACC-
CACGAACTCG-30 (antisense). The unmethylation-specific primer
sequences were 5’-TATTTTGTTTGTATGTTGATTATTG-3’ (sense)
and 5’-AAACTCAACACACAACCACTC-3’ (antisense). The un-
methylated reaction was predicted to yield a product of 122bp and
the methylated reaction a product of 132bp. PCR products were
resolved in 3% agarose gels, stained with ethidium bromide and
visualised under UV illumination. DNA extracted from normal
pancreatic tissue treated in vitro by Sss1 methyltransferase (New
England Biolabs, Beverly, MA, USA) was used as a positive control
for methylated alleles.
Reverse-transcription–PCR
RNA from pancreatic cancer cell lines was isolated using Trizol
Reagent (Life Technologies, Rockville, MD, USA). One microgram
of each total RNA was reverse transcribed (RT) using the
Superscript II kit (Life Technologies, Rockville, MD, USA). RT–
PCR primers for exon 1 were 50-GACGCCTGCGGATTCTAC-30
(sense) and 50-AGCGGCCGGCCTGAAAG-30 (antisense). A 181bp
was amplified according to the following conditions; an initial
denaturation at 951C for 3min, then 35 cycles of 951C for 15s, 651C
for 30s and 721C for 30s, followed by a final extension step at 721C
for 3min. PCR mixture contained 5% dimethyl sulphoxide. A
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primer set
was run in duplex PCR with the SOCS-1 primer to provide an
internal control for RNA quantity and quality. PCR products were
separated in 3% agarose gels.
5-aza-20-deoxycytidine treatment
To confirm that transcriptional repression related to the methyla-
tion status of the SOCS-1 CpG island, SOCS-1-methylated cells
(PL10 and PL12) were treated with the demethylating agent 5-aza-
20-deoxycytidine (5Aza-dC) at a final concentration of 1.0mM for
96h. After treatment, total RNA was extracted from the cells again
and compared the SOCS-1 gene expression to that of untreated
cells.
Western blotting analysis
Western blotting analysis was performed using antibodies specific
for phosphorylated JAK2 (anti-JAK2 pYpY
1007/1008 rabbit poly-
clonal antibody, BioSource International, CA, USA) or phosphory-
lated STAT3 (anti-pStat3, B-7, mouse monoclonal antibody, Santa
Cruz Biotechnology, CA, USA) to investigate the JAK2 and STAT3
phosphorylation status after IL-6 treatment (20ngml
 1 recombi-
nant human IL-6 , BD Biosciences, San Diego, CA, USA). After 96h
treatment of IL-6, culture cells (HPDE, Panc1, PL10 and PL12)
were lysed in cell lysis buffer (50mM Tris-HCl, pH 8.0; 50mM
ethylenediamine tetraacetic acid (EDTA); 150mM NaCl; 50ml Triton
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sX-100; 5ml Protease Inhibitor Cocktail) and boiled for 4min. After
50ml of each sample was subjected to SDS–polyacrylamide gel
electrophoresis, proteins were transferred to nitrocellulose mem-
branes (Amersham Pharmacia Biotech UK Limited, England) and
probed with each antibody. After 2h treatment with the secondary
antibody, specific binding was detected by the enhanced chemi-
luminescence system (SuperSignal
sWest Pico Luminol/Enhancer
Solution and Stable Peroxide Solution, PIERCE, Rockford, IL,
USA).
Examination of cell proliferation in response to exogenous
IL-6
To investigate the effect of methylation of SOCS-1 gene and its
silencing on the JAK/STAT pathway, cells were grown with or
without adding human IL-6 and the cell proliferation was
observed. SOCS-1-methylated (PL10 and PL12) or unmethylated
(HPDE and Panc1) cells were seeded at equal densities
(1 10
4cellsml
 1) in six-well plates. After 72h, cells were
incubated in the presence or absence of 20ngml
 1 recombinant
human IL-6 (BD Biosciences, San Diego, CA, USA) for 48, 72 or
96h. To examine the dose-dependent effect on cell proliferation of
IL-6, cells were incubated in the existence or absence of 4, 20 or
100ngml
 1 IL-6 for 96h in the same way. Cells were counted using
a haemacytometer (Hausser Scientific, Horsham, PA, USA).
Statistical analysis
Statistical analysis was performed using the StatView 5.0 statistical
software package (SAS Institute Inc., Cary, NC, USA). The
unpaired t-test was used to determine statistical differences of cell
proliferation in between IL-6 treated and untreated cells. A P-value
of less than 0.05 was considered to indicate statistical significance.
RESULTS
Methylation of SOCS-1 in pancreatic tissues
MSP analysis revealed aberrant methylation of SOCS-1 in six of 19
(31.6%) pancreatic cancer cell lines (Table 1). The cell lines
harbouring methylated SOCS-1 were PL9, PL10, PL12, Capan1,
Capan2 and MiaPaCa2. Complete or almost complete methylation
was seen in the cell lines PL9, PL10 and PL12. An example of an
MSP analysis is shown in Figure 1A.
Thirteen of 60 (21.7%) resected primary pancreatic ductal
adenocarcinomas showed SOCS-1 CpG island methylation
(Table 1). There was no significant difference in the age of
patients with unmethylated SOCS-1 (65.8 years; range, 38–85
years) and methylated SOCS-1 (65.1 years; range, 46–83 years) in
their primary pancreatic cancers. DNA from normal pancreatic
ducts (n¼16) and from 49PanINs obtained from the resection
specimens of patients with pancreatic adenocarcinoma did not
show methylation of CpG island of SOCS-1 gene (Table 1).
Lymphocyte DNA from healthy individuals also only contained
unmethylated SOCS-1 DNA (n¼11).
Aberrant methylation of the SOCS-1 CpG islands was detected in
two (5.9%) of 34 IPMNs (Table 1). Both of them were IPMNs with
associated invasive carcinoma. One of these two patients with
methylated SOCS-1 in their cancer was a patient with Peutz-Jeghers
syndrome.
Relation between aberrant methylation and gene
expression of SOCS-1
SOCS-1 gene expression was silenced or markedly reduced in seven
of 19 cell lines relative to GAPDH by RT–PCR (Figure 1B). Five of
the six methylated SOCS-1 cell lines had markedly reduced or
absent SOCS-1 gene expression. To investigate whether the
suppression of SOCS-1 gene expression was mediated by methyla-
tion of CpG islands in human pancreatic cancer cells, we treated
the pancreatic cancer cell lines PL10 and PL12 cells with 5-Aza-dC.
Both cell lines showed loss of SOCS-1 gene expression and both
harboured methylated SOCS-1 prior to treatment with 5-Aza-dC. 5-
Aza-20-deoxycytidine restored SOCS-1 gene expression (Figure 2).
Despite 5-Aza-dC induction of SOCS-1 gene expression, 5-Aza-dC
treatment did not lead to induction of JAK2 or pSTAT3, perhaps
because of the relatively modest induction of SOCS-1 gene
expression by 5-Aza-dC.
Effect of exogenously added IL-6 on proliferation of
pancreatic cancer cells
Treatment of SOCS-1-methylated pancreatic cancer cells (PL10 and
PL12) and the unmethylated cell line Panc-1 and a non-neoplastic
pancreatic ductal epithelial cell line (HPDE) with IL-6 (20ngml
 1)
for 48, 72 or 96h, led to modest but significant increases in PL10
cell growth over control in a time (data not shown) and in a dose-
dependent fashion (Figure 3). After 96h, IL-6 treatment of PL10
resulted in significant increases in cell number (120.5721.9%,
P¼0.015) compared to untreated cells, whereas two other
pancreatic cancer cell lines, Panc1 and PL12, and the non-
neoplastic HPDE cells did not change their growth patterns in
response to IL-6 (Panc1: 111720.8% (P¼0.146), PL12:
Table 1 Summary of the results of SOCS-1 MSP
n Methylation of SOCS-1 Frequency
Pancreatic cancer cell line 19 6 31.6%
Primary pancreatic cancer 60 13 21.7%
IPMNs 34 2
a 5.9%
PanINs 49 0 0%
Normal pancreatic duct epithelium 15 0 0%
Lymphocytes from healthy people 11 0 0%
IPMNs¼intraductal papillary-mucinous neoplasms; PanINs¼pancreatic intraepithe-
lial neoplasias.
aIPMN with associated invasive carcinoma.
U  M    U   M   U   M    U  M    U   M   U   M   U  M
(1)       (2)       (3)        (4)        (5)       (6)      (7)
100 bp
Figure 1 Methylation-specific PCR of SOCS-1 gene CpG islands. A visible
PCR product in lane-U indicates the presence of unmethylated gene
promoters; the presence of product in lane-M indicates the presence of
promoter methylation. (1) Panc1; (2) BxPC3; (3) Colo357; (4) AsPC1; (5)
PL9; (6) PL12; and (7) normal lymphocytes.
SOCS-1 methylation: ____+ + _ + __ _ ++   __ _ + __ _
PL1
PL3
PL4
PL6
PL9
PL10
PL11
PL12
PL14
Capan1
Capan2
Panc1
BxPC3
AsPC1
CFPac1
MiaPaca
Colo357
PL13
GAPDH
SOCS-1
Hs766T
HPDE
5-Aza-dC treatment
GAPDH
SOCS-1
_   + _   +
PL12 PL10
A
B
Figure 2 (A) SOCS-1 gene expression in RT–PCR. SOCS-1 gene
expression was silenced or strongly reduced in PL1, PL3, PL4, PL9, PL10,
PL11 and PL12, and moderately in PL6, Capan1, Capan2, AsPC1 and
CFPac1. (B) SOCS-1 gene expression is restored after 5-Aza-dC treatment.
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s11677.41% (P¼0.109), HPDE: 98.7716.4% (P¼0.807))
(Figure 3A). Stimulation by IL-6 would be expected to lead to an
induction of phosphorylated JAK2 and STAT3. Despite this
prediction, Western blotting analysis revealed that phosphorylated
JAK2 was only minimally induced after IL-6 treatment in PL12 but
not in PL10 (Figure 4). Phosphorylated STAT3 was present in all
cell lines and IL-6 treatment resulted in an increase in pSTAT3 in
the SOCS-1-methylated cell lines, PL10 and PL12, but not in the
unmethylated cell line Panc-1 (Figure 4). IL-6 treatment also
increased pSTAT3 in the pancreatic epithelial non-neoplastic cell
line, HPDE (Figure 4).
DISCUSSION
In this study, we demonstrate that SOCS-1 is a frequent target for
aberrant methylation in pancreatic cancer. We also demonstrate
that silencing of SOCS-1 gene expression occurs in pancreatic
cancer cell lines harbouring methylated SOCS-1 and such silencing
could be restored after 5-Aza-dC treatment, indicating that
methylation was the likely mechanism by which the SOCS-1 gene
expression was suppressed. Furthermore, we demonstrated that
IL-6 induced modest increases in cell proliferation only in
pancreatic cancer cells (PL10) harbouring methylated SOCS-1 gene.
Since SOCS-1 suppresses the JAK/STAT pathway by inhibiting
JAK2 activity (Kishimoto and Kikutani, 2001), and since STAT3 is
downstream of JAK2 in the JAK/STAT pathway, SOCS-1 methyla-
tion status may affect the level of phosphorylation of STAT3. We
observed a moderate induction of phosphorylated STAT3 in PL10
and PL12 after IL-6 treatment with little or no induction in an
unmethylated cell line (Panc-1). This is consistent with our
hypothesis that pSTAT3 induction by IL-6 would be more likely to
occur if SOCS-1 is methylated than if it is unmethylated. We did
not observe induction of pSTAT3 or JAK2 by 5-Aza-dC treatment
despite induction of SOCS-1, but we suspect that the level of
induction of SOCS-1 expression by 5-Aza-dC was insufficient to
result in a change in pSTAT3. There was not a clear-cut relation
between pSTAT3 levels and SOCS-1 expression and we suspect that
this observation reflects the fact that STAT3 is regulated not only
by JAK2 but also by other factors including the insulin-like growth
factor-1 receptor (IGF-R) and Src (Yu et al, 1995).
Methylation of CpG island of SOCS-1 gene appears to occur late
in the development of pancreatic ductal adenocarcinoma. PanINs
are preinvasive intraductal lesions (Hruban et al, 2001), and
PanINs harbour many of the same genetic and epigenetic
abnormalities seen in invasive ductal adenocarcinomas such as
mutations of the K-ras (Moskaluk et al, 1997), p16 (Moskaluk et al,
1997; Wilentz et al, 1998), SMAD4 (Wilentz et al, 2000), p53 and
BRCA2 genes (Goggins et al, 2000), and aberrant methylation of
the ppENK, p16 and TSLC1genes albeit at lower frequencies than
those seen in invasive pancreatic cancers (Fukushima et al, 2002;
Jansen et al, 2002). In contrast, in this study we found that PanINs
lacked methylation of SOCS-1 suggesting that if loss of SOCS-1 is a
selected event, it does not provide a selective advantage to a
pancreatic neoplasm until the neoplasm has evolved into an
invasive adenocarcinoma.
IPMN is clinicopathologically distinct neoplasm from ductal
adenocarcinoma (Fukushima et al, 1997; Longnecker et al, 2000).
Intraductal papillary mucinous neoplasms show duct ectasia with a
papillary growth of neoplastic mucin producing epithelial cells.
Patients with IPMNs generally have better prognosis than the
patients with usual pancreatic ductal adenocarcinoma; however,
some IPMNs evolve into invasive carcinoma and those patients
have a poorer outcome. Intraductal papillary mucinous neoplasms
have been shown to have similar methylation patterns to PanINs
and usual pancreatic adenocarcinomas. For example, ppENK and
p16 methylation occurs at a higher frequency in high-grade IPMNs
(carcinomas) than it does in low-grade IPMNs (adenoma or
borderline neoplasms) (Sato et al, 2002). In this study, we detected
aberrant methylation of SOCS-1 gene in only two of 14 IPMNs that
had an associated infiltrating carcinoma. None of the 20 benign or
borderline IPMNs without an associated invasive carcinoma
harboured SOCS-1 methylation. This suggests that, just as is true
for usual ductal pancreatic adenocarcinoma, aberrant methylation
of SOCS-1 gene may occur late in the development of IPMNs.
Suppressor of cytokine signalling-1 gene can be added to the
increasing list of genes that are aberrantly methylated in pancreatic
adenocarcinomas. This list includes ppENK, p16, hMLH1, RAR
beta (Ueki et al, 2000, 2001), cyclin D2 (Matsubayashi et al, 2003)
and TSLC1 (Jansen et al, 2002). In addition to understanding the
biological significance of aberrant methylation in pancreatic
_ + _ + _ + _ +
HPDE Panc1 PL10 PL12
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Figure 3 The effect of IL-6 on proliferation of pancreatic cancer cells.
(A) IL-6 treatment increased PL10 cell number compared to untreated
cells (P¼0.015). Interleukin-6 did not significantly increase the growth of
PL12, Panc1 or HPDE. (B) Dose-dependent effects of IL-6 on the
pancreatic cancer cell line (PL10).
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IL-6 treatment
Figure 4 Western blot analysis of phosphorylated JAK2 and STAT3
protein. The 130kDa band corresponding to phosphorylated JAK2 protein.
The 92kDa band representing phosphorylated STAT3 protein was variably
induced after IL-6 treatment.
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sadenocarcinoma, the detection of aberrantly methylated DNA in
secondary fluids such as the pancreatic juice of patients with
pancreatic disease may aid in the early diagnosis of pancreatic
cancer (Fukushima et al, 2003). Since SOCS-1 methylation is only
found in a subset of pancreatic adenocarcinomas, its utility as a
diagnostic marker would only be as part of a panel of other
aberrantly methylated genes that are specifically methylated in
pancreatic cancer but not in normal pancreas.
In conclusion, SOCS-1 is commonly methylated in pancreatic
adenocarcinoma and loss of SOCS-1 in pancreatic cancer is
moderately associated with increased IL-6-mediated growth. Since
SOCS-1 methylation becomes manifest only at the invasive
carcinoma stage, detection of methylated SOCS-1 may aid in the
early detection of invasive pancreatic adenocarcinoma.
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